Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
28.8M
-
Shares change
-
+1.48M
-
Total reported value, excl. options
-
$391M
-
Value change
-
+$16.9M
-
Put/Call ratio
-
1.14
-
Number of buys
-
42
-
Number of sells
-
-29
-
Price
-
$13.60
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2016
93 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2016.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.8M shares
of 105M outstanding shares and own 27.47% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4.59M shares), JPMORGAN CHASE & CO (3.33M shares), FRANKLIN RESOURCES INC (3.17M shares), NQ HCIF GP, Ltd. (3.1M shares), WELLINGTON MANAGEMENT GROUP LLP (2.34M shares), Bank of New York Mellon Corp (2.12M shares), Arrowpoint Asset Management, LLC (1.67M shares), BlackRock Fund Advisors (1.19M shares), Polar Capital LLP (1.17M shares), and VANGUARD GROUP INC (784K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.